Delve Detect Enables Neurologists to Treat CNS Infections When Conventional Testing Fails
Delve Bio, a UCSF spin-out and pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, announced data underscoring the clinical impact of mNGS using Delve Detect to identify pathogens and enable management changes in serious central nervous system (CNS) infections. The data will be presented at the American Academy of Neurology (AAN) 2026 Annual Meeting in Chicago.
Delve Bio Announces Partnership with Broad Clinical Labs for Metagenomic Next Generation Sequencing (mNGS)
Delve Bio, a pioneer in metagenomic next generation sequencing (mNGS) for infectious diseases, and Broad Clinical Labs (BCL), the world-leading genome sequencing and testing laboratory, today announced a partnership that will bring together experts in neurology, infectious disease, and clinical genomics to rapidly scale up access to metagenomics for patients with neurological infections.
Delve Bio presents study showing utility of metagenomic next generation sequencing (mNGS) in diagnosing neurological infections
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, in collaboration with the University of California, San Francisco (UCSF), today announced data on the use of mNGS for the diagnosis of infectious causes of meningitis and/or encephalitis in real-world clinical settings. The study was presented by Charles Chiu, M.D., Ph.D., Delve Bio co-founder and Professor of Laboratory Medicine and Medicine / Infectious Diseases at UCSF, at the 76th Annual Meeting of the American Academy of Neurology (AAN) in Denver, Colorado.
Delve Bio Appoints Jim Stuart as Chief Commercial Officer
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced the appointment of Jim Stuart as chief commercial officer and Jay Wohlgemuth, M.D., to the board of directors.
Delve Bio Launches to Commercialize its Metagenomic Sequencing Platform for Infectious Disease Diagnosis
Delve Bio, a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, debuts with $35 million in Series A financing led by Perceptive Xontogeny Venture Fund II (PXV Fund II) – and joined by Section 32 and GV. The funds will be used to commercialize the company’s mNGS-based infectious disease test – which was developed by world-renowned infectious disease experts at the University of California San Francisco (UCSF) Center for Next-Gen Precision Diagnostics – and advance a pipeline of next-generation tests.
